Mr. Speaker, I am grateful for the chance to finish my remarks about Bill C-265, an act to amend the Food and Drugs Act regarding a list of therapeutic products pre-approved for special access.
In the interregnum between the first and second half of my remarks, members of my community sought me out to discuss how the bill would apply in complex cases. They reminded me of some things that should be considered at committee.
First, we should avoid loopholes that could unintentionally weaken Canada's drug approval framework or allow inappropriate products to bypass proper scrutiny. Parliament should closely examine how products would qualify for inclusion on the proposed pre-approved list. While the bill references foreign approvals and clinical evidence, committee members should ensure that those standards are clearly defined and appropriately rigorous.
Committee members should also study how oversight would function once a product is granted special access. If adverse outcomes occur, what reporting mechanisms would exist? How would Health Canada monitor safety data? Would there be transparency requirements so that Canadians can understand how these decisions are being made? Those are all reasonable questions.
Another issue that deserves scrutiny is whether pharmaceutical companies could exploit the system in unintended ways. Compassionate access programs should exist for patients, not as alternative market entry strategies for manufacturers seeking to avoid the normal approval process. Parliament should ensure that the bill would not inadvertently create incentives for companies to delay seeking full Canadian approval while still gaining widespread access through an expedited pathway.
Likewise, safeguards should ensure that access remains focused on exceptional circumstances involving serious or life-threatening conditions where comparable approved Canadian therapies do not exist.
Clinical judgment really matters in medicine, and I appreciate that the bill acknowledges the role that physicians play in emergency decision-making. However, clear guardrails would still be necessary to maintain public confidence and consistent application across the country.
We should also acknowledge that access alone does not solve every problem. Many advanced therapies are extremely expensive. Some treatments for rare diseases cost hundreds of thousands or even millions of dollars annually. Families already struggling emotionally should not be left facing impossible financial uncertainty after finally obtaining access to therapy. That broader conversation around affordability, provincial coverage and rare disease strategy must continue alongside the bill.
One thing I hope we can all agree on is that Canadians facing devastating diagnoses should not feel abandoned by their health care system. At the same time, Canadians also expect Parliament to proceed carefully when it comes to medical safety and regulatory oversight. Those principles are not in conflict.
Committee work exists precisely for bills like this one. It allows Parliament to hear from physicians, rare disease advocates, pharmacologists, regulators, patient groups, ethicists and health care administrators. It allows members to test assumptions, identify weaknesses and strengthen legislation before it advances further. It also allows parliamentarians to hear from patients. Perhaps committee study will reveal areas where the bill should be amended. Perhaps stronger oversight mechanisms will be needed. Perhaps definitions will need tightening to prevent unintended consequences. That is not a flaw in the legislative process. That is the legislative process working as it should.
I also believe that Canadians are increasingly frustrated when Parliament simply shuts down debate at the outset rather than engaging constructively with proposals that may have merit. I think we will see some of that shutting down today on other matters. We should be willing to study good-faith ideas seriously, especially when they concern patients facing life-threatening illnesses.
In closing, this is an issue that Parliament should be willing to study seriously, because if we can respond and reduce delays in a responsible manner, especially for cases that are exceptional, and empower physicians while maintaining strong safeguards, then Canadians will thank us.